Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Recruiting · NCT07280702 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Phase 4 | 2026-09-01 | NCT07280702 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Texas Southwestern Medical Center | 295 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UT Southwestern Medical Center | Dallas | United States | 210 |